Project Grant F32CA284723
Award Date
1/1/25
Completion Date
6/30/26
Dollars Obligated
$149K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $169,344 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to conduct research aimed at improving adoptive cell therapy (ACT) for pancreatic cancer. The key objectives are to: 1) Identify targetable T cell-intrinsic epigenetic regulators of ACT T cell dysfunction in the tumor microenvironment, and 2) Identify targetable intra-tumor cellular...
This $166,037 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to determine the impact of CDK4/6 inhibition on the progression of intraductal papillary mucinous neoplasms (IPMN), a precursor to pancreatic cancer. The research will be conducted by the University of California, San Diego, leveraging genetically modified mouse models and patient-derived xenograft models to analyze tumor progression, survival, and the tumor...
This $530,015 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the Fred Hutchinson Cancer Center in Seattle, Washington to investigate the immunomodulatory effects of natural killer (NK) cells on anti-tumor immune responses. The overarching goal is to define the cellular and molecular mechanisms regulating NK cell phenotype and function in the tumor microenvironment, with a specific focus on understanding how...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $548,915 to the Fred Hutchinson Cancer Center in Seattle, WA to investigate a novel tumor suppressive pathway in small cell lung cancer (SCLC). The research aims to leverage cellular models, genetically engineered mouse models, and human tumor datasets to elucidate the biological roles of the stress-activated protein kinase (SAPK) axis in...
The federal Project Grant award of $2,288,000 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance. The purpose of the award is to conduct research aimed at "Targeting Epidermal Plasticity to Prevent Triple Negative Breast Cancer". The research will take place in Seattle, WA over a four-year period from April 1, 2025 through March...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $693,880 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to develop a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to overcome treatment resistance in solid tumors, such as melanoma, by engineering CD4+ T cells to express IL-12 and IL-18 to activate innate immune cells within the tumor microenvironment. The award...
This $175,978 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research by the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to study the role of ARID1A mutations in intrahepatic cholangiocarcinoma. The award period is from August 1, 2024 to July 31, 2026. The funding will support the organization's biomedical research and provision of medical care services related to...
This federal Project Grant award of $436,431 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to target metabolic crosstalk in pancreatic ductal adenocarcinoma (PDA). The University of California, Irvine is the prime awardee, conducting fundamental investigations into mechanisms that maintain cancer cell heterogeneity and metabolic symbiosis in PDA tumors. The research aims to identify oncogenic and stress pathways that can be targeted to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $584,872 to the Fred Hutchinson Cancer Center (doing business as the Seattle Cancer Care Alliance) to conduct research aimed at understanding and targeting genomic instability in myelodysplastic syndromes (MDS).
The research under this 5-year grant seeks to elucidate the molecular mechanisms underlying the sensitivity of MDS cells with RNA splicing mutations to...
The Johns Hopkins University was awarded a $431,561 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research aimed at elucidating the role of the HMGA1 chromatin regulator in pancreatic ductal adenocarcinoma (PDAC) progression and the tumor microenvironment (TME). The research project seeks to precisely define HMGA1-dependent mechanisms in PDAC tumor progression using mouse models and primary human tumors, as well as...